Gubra A/S
CSE:GUBRA
Net Margin
Gubra A/S
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DK |
G
|
Gubra A/S
CSE:GUBRA
|
5.9B DKK |
7%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
996.9B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
184B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.6B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
73T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.8B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.9B CNY |
32%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.5B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32.7B USD |
8%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.3B USD |
21%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.3B EUR |
8%
|
Gubra A/S
Glance View
Nestled in the scientific hub of Denmark, Gubra A/S has carved a niche for itself in the dynamic world of biotechnology. Since its inception in 2008, the company has anchored its reputation on its pioneering work in preclinical contract research. At its core, Gubra specializes in providing pivotal insights and support for pharmaceutical giants working on metabolic and fibrotic diseases. Through meticulous study and advanced technological frameworks, such as their proprietary imaging platforms and tailored animal models, Gubra delivers essential data that propels drug discovery forward. Their B2B model thrives on collaborating with major pharmaceutical firms, assisting them in navigating the complex maze of early-stage drug development. Beyond its contract research capabilities, Gubra has also ventured into developing its own proprietary pipeline of peptide-based drug candidates. This dual-strategy approach demonstrates their deft versatility—balancing service-based revenue streams with the potential high returns from successful drug development. While their focus remains predominantly on addressing metabolic ailments like diabetes and obesity, the company's exploration into fibrosis shows a forward-thinking attitude towards expanding their portfolio. By combining cutting-edge research with strategic alliances, Gubra continues to position itself as a vital player in biotech, capturing the synergies between scientific innovation and commercial application.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Gubra A/S's most recent financial statements, the company has Net Margin of 6.5%.
You don't have any saved screeners yet